Pharmaceuticals & Biotech U.K. Community

Active Pipeline: HG-CT-1 - Hemogenyx CAR-T for R/R AML + expanding to pediatrics in H1 2025 targeting FLT3 which has recently been proven as an extremely promising and effective target. Significant interest in CAR-T treatments with each treatment 200k+, licensing deals in the range of 500m->1bn+ (including milestone payments) CDX - Building on same FLT3 target expands use of bi-specific antibody to a whole range of blood borne cancers and diseases including auto-immune.

Key Takeaways Expansion in the porcine business and PRRS resistant pig commercialization boosts revenue stability and growth through innovation and market penetration. Cost-saving and efficiency efforts through the Value Acceleration Programme increase operating profit, with sustainability initiatives driving customer-engaging growth.

Key Takeaways Expansion into a new facility and offering new services are expected to drive revenue growth and diversify income streams. Increased capacity for trials and focus on operational efficiencies could improve margins and enhance overall revenue.

Key Takeaways Strong growth in Specialty Medicines and new product launches expected to drive revenue, particularly in HIV, Respiratory, and Oncology. Expanding portfolio with new vaccines and HIV advancements anticipated to impact earnings and market share positively.